Aggarwal Rohit
Known title: Division PresidentCIK: 0001678657
Associated companies
Transaction History
| HUN | ▲ Buy | Option Exercise | 3,376 | — | 2/17/2023 | View on chart |
| HUN | ▲ Buy | Option Exercise | 1,410 | — | 2/17/2023 | View on chart |
| HUN | ▲ Buy | Grant | 13,928 | $0 | 2/16/2023 | View on chart |
| HUN | ▲ Buy | Option Exercise | 3,095 | — | 2/13/2023 | View on chart |
| HUN | ▲ Buy | Option Exercise | 3,376 | — | 2/17/2022 | View on chart |
| HUN | ▲ Buy | Option Exercise | 3,095 | — | 2/11/2022 | View on chart |
| HUN | ▲ Buy | Option Exercise | 2,942 | — | 2/4/2022 | View on chart |
| HUN | ▲ Buy | Grant | 9,930 | $0 | 1/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Huntsman Faces New Coverage and Lowered Price Targets
Barclays initiated coverage on Huntsman with an Equal-Weight rating and a $10 price target. Meanwhile, Wells Fargo maintained its Equal-Weight stance but lowered its target to $9. These updates place the stock near the lower end of the $9 to $14 analyst range, reflecting cautious expectations for the company's performance.
Huntsman Faces New Coverage and Lowered Price Targets. Barclays initiated coverage on Huntsman with an Equal-Weight rating and a $10 price target. Meanwhile, Wells Fargo maintained its Equal-Weight stance but lowered its target to $9. These updates place the stock near the lower end of the $9 to $14 analyst range, reflecting cautious expectations for the company's performance.